Yep. An unforseen catalyst might be sticking to a Q4 2021 Phase 1 DMT clinical trial. Depending on how fast they can get results and if positively overwhelming, it might lead to a partnership as rumored at stock twits. It appears that nearly no one on the message boards tuned into yesterday's event and if they did they're not sharing any information. It kinda shows how disinterested investors are since bombing out miserably with COVID. Time will tell and Q1 2022 will likely tell the story for the rest of 2022.
Patent protection is going to be big here.. Can they go after CNS market as well with nerve growth?
Expand the patent now.. competing market place. Review Anavex’s Path amd follow it Bring in foundations to help cover research amd clinical Costs.. NOW
News 
Market Data 
Discover 
